K-5a2
K-5a2 is the non-isotopic form of ZK-316 (HY-173427S). ZK-316 is a potent and broad-spectrum NNRTI inhibitor with an EC50 value ranging from 0.99 to 75.1 nM. ZK-316 can be used in the study of HIV.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 1810730-10-9
- Formel: C27H28N6O3S2
- Molecular Weight:548.68
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
0.13 μM
Compound: 3; K-5a2
|
Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay
Inhibition of human ERG expressed in HEK293 cells assessed as reduction in channel tail current by whole cell patch clamp assay
|
[PMID: 31935327] |
| HEK293 | IC50 |
0.13 μM
Compound: 3; K-5a2
|
Inhibition of human ERG expressed in HEK293 cells by whole cell electrophysiology assay
Inhibition of human ERG expressed in HEK293 cells by whole cell electrophysiology assay
|
[PMID: 32293182] |
| MT4 | CC50 |
>227 μM
Compound: K-5a2
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 32200201] |
| MT4 | CC50 |
>227890 nM
Compound: 27
|
Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 27541578] |
| MT4 | EC50 |
>=227890 nM
Compound: 27
|
Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV2 ROD harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
|
[PMID: 27541578] |
| MT4 | EC50 |
1.4 nM
Compound: 27
|
Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
|
[PMID: 27541578] |
| MT4 | EC50 |
2.9 nM
Compound: 27
|
Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
|
[PMID: 27541578] |
| MT4 | EC50 |
2.9 nM
Compound: 27
|
Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
|
[PMID: 27541578] |
| MT4 | EC50 |
3 nM
Compound: 27
|
Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
|
[PMID: 27541578] |
| MT4 | EC50 |
3.2 nM
Compound: 27
|
Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
|
[PMID: 27541578] |
| MT4 | EC50 |
3.4 nM
Compound: 27
|
Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
|
[PMID: 27541578] |
| MT4 | EC50 |
4.2 nM
Compound: 27
|
Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
|
[PMID: 27541578] |
| TZM | CC50 |
>227 nM
Compound: 3; K-5a2
|
Cytotoxicity against human TZM-bl cells after 4 days by XTT assay
Cytotoxicity against human TZM-bl cells after 4 days by XTT assay
|
[PMID: 30624934] |
Chemical Information
-
CAS. Nr. 1810730-10-9
-
Molecular Weight 548.68
-
Formel C27H28N6O3S2
-
SMILES
N#CC1=CC(C)=C(OC2=C3SC=CC3=NC(NC4CCN(CC4)CC5=CC=C(C=C5)S(=O)(N)=O)=N2)C(C)=C1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)